ReviewMolecules (Basel, Switzerland)2021
P2Y
Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Gut microbiota and glioblastoma: composition, mechanisms, and therapeutic interventions.Infectious agents and cancer · 2026Review
- The CD73-adenosine axis in melanoma: from multidimensional regulation to precision immunotherapy.Frontiers in immunology · 2026Review
- Role and recent progress of P2Y12 receptor in cancer development.Purinergic signalling · 2025Review
- Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- [Acta pharmaceutica Sinica. B · 2025Article
- Metastasis and angiogenesis in cervical cancer: key aspects of purinergic signaling in platelets and possible therapeutic targets.Purinergic signalling · 2024Review
- Update on the mechanism of microglia involvement in post-stroke cognitive impairment.Frontiers in aging neuroscience · 2024Review
- The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer.Frontiers in immunology · 2024Review
- Review
- Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Platelets in the tumor microenvironment and their biological effects on cancer hallmarks.Frontiers in oncology · 2023Review
- P2YPurinergic signalling · 2022Article
- The functional role of p38 MAPK pathway in malignant brain tumors.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Gliomas are the most common malignant brain tumors in adults, characterized by a high proliferation and invasion. The tumor microenvironment is rich in growth-promoting signals and immunomodulatory pathways, which increase the tumor's aggressiveness. In response to hypoxia and glioma therapy, the amounts of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) strongly increase in the extracellular space, and the purinergic signaling is triggered by nucleotides' interaction in P2 receptors. Several cell types are present in the tumor microenvironment and can facilitate tumor growth. In fact, tumor cells can activate platelets by the ADP-P2Y
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.